Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, et al. N Engl J Med 2020;382:41-50.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 2020;382:41-50.
PMID: 31751012